Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D3S-001 Monotherapy or Combination Therapy in Advanced Solid Tumors With KRAS p.G12C Mutation
NCT05410145Phase 2Recruiting
- Sponsor
- D3 Bio
- Start
- Aug 2022
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of elisrasib in solid tumor, sponsored by D3 Bio. Started Aug 2022; status: recruiting.
02
Drugs
elisrasib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05410145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410145.